|
Patent landscape, scope, and claims: |
US Patent 12,410,189 Scope, Claims, and US Patent Landscape for Crystalline Form A/B/D of a (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide (Breast Cancer Treatment)
Executive summary: US Patent 12,410,189 is a US method-of-treatment patent that ties breast cancer treatment to administration of specific crystalline hydrate/anhydrate polymorphs of a single chiral small molecule, with polymorph identity defined by X-ray powder diffraction (XRPD) peak positions and supporting thermal/spectroscopic descriptors. Independent claim coverage is directed to the use of Form A (anhydrate), Form D (anhydrate), and Form B (trihydrate) polymorphs, with dependent claims narrowing by biomarker status (HR+, HR+/HER2−, PIK3CA mutant types) and optional combination regimens with a broad list of oncology drugs. For an IP risk assessment in the US, the core litigation/clearance question is whether a generic or branded competitor’s commercial solid form matches any claimed polymorph definition (Form A/Form B/Form D) closely enough to meet the XRPD-based peak requirements, including the additional Form A embodiments that specify extra peak sets and DSC/SSNMR confirmation.
What is US Patent 12,410,189 claiming, and how broad is the method-of-use coverage?
Short answer: It claims breast cancer treatment by administering an “effective amount” of one of three crystalline polymorphs of a specific stereochemically defined compound, with polymorph identity enforced by XRPD peak patterns (independent claims 1–3) and narrowed by cancer biomarkers and combination therapy (dependent claims 4–10, 15–18).
Claim architecture and what it means commercially
The claims are structured as:
-
Independent method-of-treatment claims to administer the drug substance in a specific crystalline polymorph state:
- Claim 1: Form A (crystalline anhydrate) XRPD peaks at ~2θ 5.7, 11.4, 19.0 (plus a later dependent variant that adds more peaks).
- Claim 2: Form D (crystalline anhydrate) XRPD peaks at ~2θ 7.5, 8.6, 10.8, 16.8, 19.2, 20.4.
- Claim 3: Form B (crystalline trihydrate) XRPD peaks at ~2θ 5.4, 10.5, 25.2.
-
Dependent claims that narrow patient subpopulations and regimen:
- Biomarkers: HR+ (claims 4, 15), HR+/HER2− with PIK3CA mutations (claim 5), and specific PIK3CA mutant variants (claims 6, 16, 18).
- Combination therapy: “one or more additional therapeutic agents” (claims 7–10, 9–10) listing multiple oncology drugs and classes, including CDK4/6 inhibitors, SERDs, aromatase inhibitors, and specific exemplars (palbociclib, fulvestrant, letrozole).
- Form identification reinforcement: extra peak sets and orthogonal analytics for Form A (claims 11–14).
Practical breadth
- Drug identity is fixed: all independent claims use the same stereodefined compound name and an anhydrate/trihydrate polymorph designation (Form A/B/D).
- Therapeutic indication is limited: “method for the treatment of breast cancer in a subject in need thereof.”
- Patient subsets are further limited only in dependent claims: HR+, HR+/HER2−, and PIK3CA mutant type.
- Combination scope is broad but conditional: only triggered when additional agents are used (claims 7–10), and the list is non-exclusive (“selected from the group consisting of…” is exclusive to that set, but “one or more additional agents” gives flexibility within the listed set).
How are Form A, Form B, and Form D defined: XRPD peak patterns, DSC, and SSNMR?
Short answer: The patent operationalizes polymorph identity with XRPD 2θ peak positions, then in certain embodiments for Form A adds additional XRPD peaks, DSC melting endotherm range, and 13C/19F SSNMR reference spectra descriptors.
Independent claims: XRPD-based polymorph definitions
Claim 1 (Form A, crystalline anhydrate):
- XRPD characteristic peaks at approximately 2θ 5.7, 11.4, 19.0.
Claim 2 (Form D, crystalline anhydrate):
- XRPD characteristic peaks at approximately 2θ 7.5, 8.6, 10.8, 16.8, 19.2, 20.4.
Claim 3 (Form B, crystalline trihydrate):
- XRPD characteristic peaks at approximately 2θ 5.4, 10.5, 25.2.
Dependent claims: Form A tightening (higher evidentiary hooks)
Claim 11 (additional Form A XRPD peaks):
- Peaks at approximately 2θ 5.7, 11.4, 17.2, 19.0, 19.7, 24.4.
Claim 12 (FIG.-anchored XRPD pattern):
- Form A characterized “substantially as shown in FIG. 4.”
Claim 13 (DSC thermal anchor):
- Form A described with peaks shown in Table 2 and DSC melting endotherm at approximately 212 to 215°C.
Claim 14 (SSNMR anchors):
- Form A characterized by 13C SSNMR and 19F SSNMR substantially as shown in FIG. 7A and 7B.
IP implication for design-around
- XRPD identity is the gate. If a competitor’s commercial solid form does not exhibit the claimed “characteristic peaks” at the specified approximate 2θ values, it can avoid direct infringement of the polymorph-specific independent claims.
- But claim 11/12/13/14 increase the evidentiary standard for Form A in those dependent embodiments, which matters in litigation because it provides more objective confirmation paths (thermal and spectroscopy) beyond just three peaks.
Does US 12,410,189 cover specific breast cancer biology (HR status and PIK3CA mutation types)?
Short answer: Yes, through dependent claims 4–6 and 15–18. The independent claims do not require biomarker status. The narrowing is only in dependent claims, so the broadest protection is still tied to the polymorph administration for “breast cancer” generally.
Biomarker-dependent claim set
- Claim 4: Cancer is hormone receptor positive (HR+).
- Claim 5: HR+ and HER2-negative, expressing PIK3CA mutation.
- Claim 6: PIK3CA mutant type selected from:
- E542K, E545K, Q546R, H1047L, H1047R
- Claim 15: HR+ (dependent to claim 2).
- Claim 16: PIK3CA mutant type (dependent to claim 2).
- Claim 17: HR+ (dependent to claim 3).
- Claim 18: PIK3CA mutant type (dependent to claim 3).
Commercial interpretation
- In enforcement terms, biomarker-dependent claims can be leveraged to strengthen case theory when clinical populations in marketing or investigator brochures align with HR+/HER2− and listed PIK3CA variants.
- In clearance terms, generic entry risk is not eliminated by targeting broader unselected breast cancer populations; direct coverage starts at the polymorph administration.
What combination therapies are listed, and does that create additional infringement pathways?
Short answer: Dependent claims 7–10 add infringement pathways when the method includes “one or more additional therapeutic agents” chosen from defined oncology drug sets, including endocrine and cell-cycle targeted agents.
Dependent combination claims
Claim 7: method further comprises one or more additional therapeutic agents.
Claim 8 (specific agents listed):
- 5-FU
- docetaxel
- eribulin
- gemcitabine
- cobimetinib
- ipatasertib
- paclitaxel
- tamoxifen
- fulvestrant
- GDC-0810
- dexamethasone
- palbociclib
- bevacizumab
- pertuzumab
- trastuzumab emtansine
- trastuzumab and letrozole
Claim 9 (class-level categories):
- selected from:
- CDK4/6 inhibitor
- selective estrogen receptor degrader (SERD)
- aromatase inhibitor
Claim 10 (examples):
- palbociclib, fulvestrant, letrozole
How this affects risk
- Combination claims are easiest to attack only where the accused regimen clearly does not include any of the enumerated agents.
- If clinical labeling, compendia recommendations, or physician practice uses the listed combination(s), it supports a compliance record for infringement theories.
- If a challenger uses an alternative combination outside the enumerated list, it can reduce exposure to dependent claims, but not to polymorph-based independent claims.
How strong is US 12,410,189’s patent scope for infringement: does it require matching a “Form” exactly?
Short answer: Yes. The claims operationalize infringement around whether the administered drug corresponds to Form A, Form B, or Form D as defined by XRPD peak sets. In practice, infringement will hinge on solid-state analytical testing: XRPD for peak positions, then DSC and SSNMR for Form A dependent embodiments.
Key claim-scope levers
- Polymorph designation + XRPD “characteristic peaks”
- Claims 1–3 define polymorphs by peak positions at approx. 2θ values.
- Additional Form A constraints
- Claims 11–14 tighten Form A identity and provide multiple independent measurement anchors.
- “Effective amount” and method context
- Standard for method-of-treatment: no dosage mg claim is recited in the provided claim text, which broadens coverage across dosing regimens that produce efficacy.
Litigation posture implications
- For plaintiffs, the XRPD peak requirements give a crisp technical standard.
- For defendants, the pathway is solid-form control: generate, purchase, or manufacture a solid form not meeting the claimed XRPD peak pattern set.
- Mixed-form materials (partially converted polymorphs) can become a factual battleground: the question becomes whether the administered material meets the claim-defined “characteristic peaks,” not whether a minor fraction exists.
What is the US patent landscape around US 12,410,189: continuation families, solid-form competitors, and likely adjacent claims?
Short answer: The provided claim set is typical of a solid-state patent strategy: new crystalline form claims paired with patient-indication-dependent method claims. The landscape risk is usually driven by (i) other polymorph patents in the same family, (ii) process/seed/conditions patents for crystallization control, and (iii) earlier composition patents covering the same active compound in non-crystalline or different crystalline forms.
No definitive landscape mapping is possible from the provided information alone because the patent bibliographic record (assignee, filing dates, priority dates, family members, examiner-cited patents, and prosecution history) is not supplied. Under the constraints, this analysis cannot identify other specific US patents, continuation application numbers, or related Orange Book listings tied to the same drug substance.
When does US 12,410,189 lose exclusivity or reach patent expiration, and what determines generic timing?
Short answer: Cannot be determined from the claim text alone because US patent term depends on the patent’s filing/priority dates and any PTA adjustments, and regulatory exclusivity timing depends on the specific product’s FDA approval date and patent listing in the Orange Book.
No expiration timeline is produced because the necessary bibliographic and regulatory data is not present.
What FDA pathway and Orange Book status would matter for Paragraph IV challenges?
Short answer: The legal relevance is high if the active is listed in the Orange Book with polymorph-specific patents (drug substance/formulation) and if an NDA/BLA-holder listed US 12,410,189 for the approved product(s). A Paragraph IV challenge would then argue non-infringement (solid form not matching claimed Form A/B/D) and/or invalidity (e.g., lack of novelty/obviousness over prior art polymorphs).
Orange Book status cannot be stated from the provided inputs because no NDA/BLA number, listed drug name, or Orange Book patent listing identifiers are included.
How do you compare patent estates for crystalline polymorph methods: what competitors typically target?
Short answer: Competitors typically target one of three axes: (1) avoiding the claimed polymorph by manufacturing a different solid form, (2) avoiding the claimed XRPD peak pattern by using a form within close but distinct polymorph space, or (3) avoiding dependent claim combinations and biomarker populations through labeling and regimen choices.
This patent’s core axis is solid form and XRPD peak identity. Therefore, comparisons between different solid-form estates in the same molecule class will be decided by the strictness and uniqueness of their XRPD peak definitions, and whether the claims include orthogonal constraints (DSC/SSNMR) that reduce ambiguity.
Key Takeaways
- US 12,410,189 is a polymorph-defined method-of-treatment patent for breast cancer using a single stereochemically specified small molecule, with independent claims to Form A (anhydrate), Form D (anhydrate), and Form B (trihydrate).
- XRPD peak positions are the infringement trigger for Forms A/B/D. Form A has additional XRPD, DSC melting range, and SSNMR support in dependent claims, tightening identity.
- Broader breast cancer coverage is independent of HR/PIK3CA; biomarker and HER2 status appear in dependent claims only.
- Combination regimens create additional exposure only when the additional agents used fall within the enumerated list and classes (including CDK4/6 inhibitors and endocrine agents).
- Solid-form design-around is the dominant defense concept: establish that the manufactured and administered material does not meet the claimed “characteristic peaks” for the asserted Form(s).
FAQs
-
Can a competitor avoid infringement by using the same active ingredient but a different polymorph?
The claims are polymorph-specific; using a different solid form that does not meet the claimed XRPD peak patterns is the primary non-infringement pathway.
-
Does US 12,410,189 require HR+/HER2− or PIK3CA mutation to be infringed?
No. Those biomarkers appear in dependent claims; independent claims cover breast cancer generally.
-
Are combination therapy claims enforceable if physicians use a drug outside the listed “consisting of” set?
Dependent combination claims are limited to the enumerated set; use outside the set is not within the “selected from… consisting of” limitation.
-
How important is DSC and SSNMR in proving Form A infringement?
They are used in dependent embodiments to define Form A more robustly beyond XRPD, which can strengthen evidentiary proof.
-
What analytical work matters most in evaluating claim scope for a generic solid form?
XRPD is central for Forms A/B/D; DSC and SSNMR become important for Form A-dependent claim embodiments.
References
- United States Patent 12,410,189 (claim text provided in prompt).
More… ↓
⤷ Start Trial
|
